In light of the recent results showing a reduction in associated all-cause mortality in the ODYSSEY Outcomes Trial, which patients deserve our greatest attention to optimize the translational impact of this study?

In light of the recent results showing a reduction in associated all-cause mortality in the ODYSSEY Outcomes Trial, which patients deserve our greatest attention to optimize the translational impact of this study?

CLICK HERE FOR CME CREDIT

 From your perspective as both an IC and lipid medicine specialist, in light of the recent results showing a reduction in associated all-cause mortality in the ODYSSEY Outcomes Trial, which patients deserve our greatest attention to optimize the translational impact of this study?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Interventional Cardiologist's Perspective

Presenter

J. Wouter Jukema, MD, PhD, FESC, FACC MC

J. Wouter Jukema, MD, PhD, FESC, FACC MC

Professor of Cardiology Netherlands Heart Foundation Chairman, Leiden Vascular Medicine Leiden University Medical Center (LUMC) Leiden, Netherlands